Acute kidney injury is a common complication in critically ill patients with sepsis and/or septic shock. Further, some essential antimicrobial treatment drugs are themselves nephrotoxic. For this reason, timely diagnosis and adequate therapeutic management are paramount. Of potential acute kidney injury (AKI) biomarkers, non-protein-coding RNAs are a subject of ongoing research. This review covers the pathophysiology of vancomycin and gentamicin nephrotoxicity in particular, septic AKI and the microRNAs involved in the pathophysiology of both syndromes. PubMED, UptoDate, MEDLINE and Cochrane databases were searched, using the terms: biomarkers, acute kidney injury, antibiotic nephrotoxicity, sepsis, miRNA and nephrotoxicity. A comprehensive review describing pathophysiology and potential biomarkers of septic and toxic acute kidney injury in septic patients was conducted. In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified. However, while these are at the stage of clinical testing, preclinical and clinical trials are needed before they can be considered useful biomarkers or therapeutic targets of AKI in the context of antibiotic nephrotoxicity or septic injury.

Department of Anesthesiology and Resuscitation University Hospital Ostrava 70852 Ostrava Czech Republic

Department of Biomedical Sciences Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Department of Clinical Studies Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Department of Internal Medicine 3 Nephrology Rheumatology and Endocrinology University Hospital and Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Olomouc Czech Republic

Department of Internal Medicine University Hospital Ostrava 70852 Ostrava Czech Republic

Department of Laboratory Diagnostics Institute of Clinical Biochemistry and Clinical Pharmacology University Hospital Ostrava 70852 Ostrava Czech Republic

Institute of Clinical Pharmacology Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Zobrazit více v PubMed

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012;2:1–138.

Chawla L.S., Bellomo R., Bihorac A., Goldstein S.L., Siew E.D., Bagshaw S.M., Bittleman D., Cruz D., Endre Z., Fitzgerald R.L., et al. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 2017;13:241–257. doi: 10.1038/nrneph.2017.2. PubMed DOI

Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., Schetz M., Tan I., Bouman C., Macedo E., et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA. 2005;294:813–818. PubMed

Jiang L., Zhu Y., Luo X., Wen Y., Du B., Wang M., Zhao Z., Yin Y., Zhu B., Xi X. Epidemiology of acute kidney injury in intensive care units in Beijing: The multi-center BAKIT study. BMC Nephrol. 2019;20:468. doi: 10.1186/s12882-019-1660-z. PubMed DOI PMC

Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287. PubMed DOI PMC

Poston J.T., Koyner J.L. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891. doi: 10.1136/bmj.k4891. PubMed DOI PMC

Gómez H., Kellum J.A. Sepsis-induced acute kidney injury. Curr. Opin. Crit. Care. 2016;22:546–553. doi: 10.1097/MCC.0000000000000356. PubMed DOI PMC

Ronco C., Bellomo R., Kellum J.A. Acute kidney injury. Lancet. 2019;394:1949–1964. PubMed

Anders H.J., Banas B., Schlöndorff D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J. Am. Soc. Nephrol. 2004;15:854–867. doi: 10.1097/01.ASN.0000121781.89599.16. PubMed DOI

Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 2007;13:460–469. PubMed

Morrell E.D., Kellum J.A., Pastor-Soler N.M., Hallows K.R. Septic acute kidney injury: Molecular mechanisms and the importance of stratification and targeting therapy. Crit. Care. 2014;18:501. doi: 10.1186/s13054-014-0501-5. PubMed DOI PMC

Wei Q. Novel strategy for septic acute kidney injury rescue: Maintenance of the tubular integrity. Kidney Int. 2020;97:847–849. PubMed

Nakano D., Kitada K., Wan N., Zhang Y., Wiig H., Wararat K., Yanagita M., Lee S., Jia L., Titze J.M., et al. Lipopolysaccharide induces filtrate leakage from renal tubular lumina into the interstitial space via a proximal tubular Toll-like receptor 4-dependent pathway and limits sensitivity to fluid therapy in mice. Kidney Int. 2020;97:904–912. doi: 10.1016/j.kint.2019.11.024. PubMed DOI

Kashani K., Cheungpasitporn W., Ronco C. Biomarkers of acute kidney injury: The pathway from discovery to clinical adoption. Clin. Chem. Lab. Med. 2017;55:1074–1089. doi: 10.1515/cclm-2016-0973. PubMed DOI

Klein S.J., Brandtner A.K., Lehner G.F., Ulmer H., Bagshaw S.M., Wiedermann C.J., Joannidis M. Biomarkers for prediction of renal replacement therapy in acute kidney injury: A systematic review and meta-analysis. Intensive Care Med. 2018;44:323–336. doi: 10.1007/s00134-018-5126-8. PubMed DOI PMC

Schrezenmeier E.V., Barasch J., Budde K., Westhoff T., Schmidt-Ott K.M. Biomarkers in acute kidney injury-pathophysiological basis and clinical performance. Acta Physiol. 2017;219:554–572. doi: 10.1111/apha.12764. PubMed DOI PMC

Teo S.H., Endre Z.H. Biomarkers in acute kidney injury (AKI) Best Pract. Res. Clin. Anaesthesiol. 2017;31:331–344. doi: 10.1016/j.bpa.2017.10.003. PubMed DOI

Izquierdo-Garcia J.L., Nin N., Cardinal-Fernandez P., Rojas Y., de Paula M., Granados R., Martínez-Caro L., Ruíz-Cabello J., Lorente J.A. Identification of novel metabolomic biomarkers in an experimental model of septic acute kidney injury. Am. J. Physiol. Renal Physiol. 2019;316:F54–F62. doi: 10.1152/ajprenal.00315.2018. PubMed DOI

Chebotareva N., Bobkova I., Shilov E. Heat shock proteins and kidney disease: Perspectives of HSP therapy. Cell Stress Chaperones. 2017;22:319–343. doi: 10.1007/s12192-017-0790-0. PubMed DOI PMC

Morales-Buenrostro L.E., Salas-Nolasco O.I., Barrera-Chimal J., Casas-Aparicio G., Irizar-Santana S., Pérez-Villalva R., Bobadilla N.A. Hsp72 is a novel biomarker to predict acute kidney injury in critically ill patients. PLoS ONE. 2014;9:e109407. doi: 10.1371/journal.pone.0109407. PubMed DOI PMC

Dozmorov M.G., Giles C.B., Koelsch K.A., Wren J.D. Systematic classification of non-coding RNAs by epigenomic similarity. BMC Bioinform. 2013;14:S2. doi: 10.1186/1471-2105-14-S14-S2. PubMed DOI PMC

Fan P.C., Chen C.C., Chen Y.C., Chang Y.S., Chu P.H. MicroRNAs in acute kidney injury. Hum. Genom. 2016;10:29. doi: 10.1186/s40246-016-0085-z. PubMed DOI PMC

Giza D.E., Fuentes-Mattei E., Bullock M.D., Tudor S., Goblirsch M.J., Fabbri M., Lupu F., Yeung S.J., Vasilescu C., Calin G.A. Cellular and viral microRNAs in sepsis: Mechanisms of action and clinical applications. Cell Death Differ. 2016;23:1906–1918. doi: 10.1038/cdd.2016.94. PubMed DOI PMC

Benz F., Roy S., Trautwein C., Roderburg C., Luedde T. Circulating MicroRNAs as Biomarkers for Sepsis. Int. J. Mol. Sci. 2016;17:78. doi: 10.3390/ijms17010078. PubMed DOI PMC

Lin Z., Liu Z., Wang X., Qiu C., Zheng S. MiR-21-3p Plays a Crucial Role in Metabolism Alteration of Renal Tubular Epithelial Cells during Sepsis Associated Acute Kidney Injury via AKT/CDK2-FOXO1 Pathway. Biomed. Res. Int. 2019;2019:2821731. doi: 10.1155/2019/2821731. PubMed DOI PMC

Ge Q.M., Huang C.M., Zhu X.Y., Bian F., Pan S.M. Differentially expressed miRNAs in sepsis-induced acute kidney injury target oxidative stress and mitochondrial dysfunction pathways. PLoS ONE. 2017;12:e0173292. doi: 10.1371/journal.pone.0173292. PubMed DOI PMC

Ishimoto Y., Inagi R. Mitochondria: A therapeutic target in acute kidney injury. Nephrol. Dial. Transplant. 2016;31:1062–1069. doi: 10.1093/ndt/gfv317. PubMed DOI

Shen Y., Yu J., Jing Y., Zhang J. MiR-106a aggravates sepsis-induced acute kidney injury by targeting THBS2 in mice model. Acta Cir. Bras. 2019;34:e201900602. doi: 10.1590/s0102-865020190060000002. PubMed DOI PMC

Taber S.S., Pasko D.A. The epidemiology of drug-induced disorders: The kidney. Expert Opin. Drug Saf. 2008;7:679–690. doi: 10.1517/14740330802410462. PubMed DOI

Rhodes A., Evans L.E., Alhazzani W., Levy M.M., Antonelli M., Ferrer R., Kumar A., Sevransky J.E., Sprung C.L., Nunnally M.E., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–377. doi: 10.1007/s00134-017-4683-6. PubMed DOI

Wilhelm-Leen E., Montez-Rath M.E., Chertow G. Estimating the Risk of Radiocontrast-Associated Nephropathy. J. Am. Soc. Nephrol. 2017;28:653–659. doi: 10.1681/ASN.2016010021. PubMed DOI PMC

Perazella M.A., Markowitz G.S. Drug-induced acute interstitial nephritis. Nat. Rev. Nephrol. 2010;6:461–470. doi: 10.1038/nrneph.2010.71. PubMed DOI

Petejova N., Martinek A., Zadrazil J., Teplan V. Acute toxic kidney injury. Ren. Fail. 2019;41:576–594. doi: 10.1080/0886022X.2019.1628780. PubMed DOI PMC

Arimura Y., Yano T., Hirano M., Sakamoto Y., Egashira N., Oishi R. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis. Free Radic. Biol. Med. 2012;52:1865–1873. doi: 10.1016/j.freeradbiomed.2012.02.038. PubMed DOI

Moledina D.G., Perazella M.A. PPIs and kidney disease: From AIN to CKD. J. Nephrol. 2016;29:611–616. doi: 10.1007/s40620-016-0309-2. PubMed DOI

Ong L.Z., Tambyah P.A., Lum L.H., Low Z.J., Cheng I., Murali T.M., Wan M.Q., Chua H.R. Aminoglycoside-associated acute kidney injury in elderly patients with and without shock. J. Antimicrob. Chemother. 2016;71:3250–3257. doi: 10.1093/jac/dkw296. PubMed DOI

Rybak M.J., Lomaestro B.M., Rotschafer J.C., Moellering R.C., Jr., Craig W.A., Billeter M., Dalovisio J.R., Levine D.P. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275–1279. doi: 10.1592/phco.29.11.1275. PubMed DOI

Zamoner W., Prado I.R.S., Balbi A.L., Ponce D. Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice. Clin. Exp. Pharmacol. Physiol. 2019 doi: 10.1111/1440-1681.13066. PubMed DOI

Rybak M.J., Le J., Lodise T.P., Levine D.P., Bradley J.S., Liu C., Mueller B.A., Pai M.P., Wong-Beringer A., Rotschafer J.C., et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2020;40:363–367. PubMed

Chavada R., Ghosh N., Sandaradura I., Maley M., Van Hal S.J. Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 2017;61 doi: 10.1128/AAC.02535-16. PubMed DOI PMC

Hanrahan T.P., Kotapati C., Roberts M.J., Rowland J., Lipman J., Roberts J.A., Udy A. Factors associated with vancomycin nephrotoxicity in the critically ill. Anaesth. Intensive Care. 2015;43:594–599. doi: 10.1177/0310057X1504300507. PubMed DOI

Sakamoto Y., Yano T., Hanada Y., Takeshita A., Inagaki F., Masuda S., Matsunaga N., Koyanagi S., Ohdo S. Vancomycin induces reactive oxygen species-dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells. Eur. J. Pharmacol. 2017;800:48–56. doi: 10.1016/j.ejphar.2017.02.025. PubMed DOI

Kane-Gill S.L., Ostermann M., Shi J., Joyce E.L., Kellum J.A. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study. Drug Saf. 2019;42:1149–1155. doi: 10.1007/s40264-019-00846-x. PubMed DOI

Rhodes N.J., Prozialeck W.C., Lodise T.P., Venkatesan N., O’Donnell J.N., Pais G., Cluff C., Lamar P.C., Neely M.N., Gulati A., et al. Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. Antimicrob. Agents Chemother. 2016;60:5742–5751. doi: 10.1128/AAC.00591-16. PubMed DOI PMC

Pang H.M., Qin X.L., Liu T.T., Wei W.X., Cheng D.H., Lu H., Guo Q., Jing L. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as early biomarkers for predicting vancomycin-associated acute kidney injury: A prospective study. Eur. Rev. Med. Pharmacol. Sci. 2017;21:4203–4213. PubMed

Pais G.M., Avedissian S.N., O′Donnell J.N., Rhodes N.J., Lodise T.P., Prozialeck W.C., Lamar P.C., Cluff C., Gulati A., Fitzgerald J.C., et al. Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. Antimicrob. Agents Chemother. 2019;63 doi: 10.1128/AAC.00079-19. PubMed DOI PMC

Wang J., Li H., Qiu S., Dong Z., Xiang X., Zhang D. MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI. Cell Death Dis. 2017;8:e3120. doi: 10.1038/cddis.2017.509. PubMed DOI PMC

Olbricht C.J., Fink M., Gutjahr E. Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int. 1991;39:639–646. doi: 10.1038/ki.1991.76. PubMed DOI

Gentamicin 40 mg/mL Injection. [(accessed on 7 July 2020)]; Available online: https://www.medicines.org.uk/emc/product/6531/smpc.

Romero F., Pérez M., Chávez M., Parra G., Durante P. Effect of uric acid on gentamicin-induced nephrotoxicity in rats-role of matrix metalloproteinases 2 and 9. Basic Clin. Pharmacol. Toxicol. 2009;105:416–424. doi: 10.1111/j.1742-7843.2009.00466.x. PubMed DOI

Martínez-Salgado C., López-Hernández F.J., López-Novoa J.M. Glomerular nephrotoxicity of aminoglycosides. Toxicol. Appl. Pharmacol. 2007;223:86–98. doi: 10.1016/j.taap.2007.05.004. PubMed DOI

Udupa V., Prakash V. Gentamicin induced acute renal damage and its evaluation using urinary biomarkers in rats. Toxicol. Rep. 2018;6:91–99. doi: 10.1016/j.toxrep.2018.11.015. PubMed DOI PMC

Campos M.A.A., de Almeida L.A., Grossi M.F., Tagliati C.A. In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J. Biochem. Mol. Toxicol. 2018;32:e22189. doi: 10.1002/jbt.22189. PubMed DOI

Kagawa T., Zarybnicky T., Omi T., Shirai Y., Toyokuni S., Oda S., Yokoi T. A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. Toxicology. 2019;415:26–36. doi: 10.1016/j.tox.2019.01.011. PubMed DOI

Hori Y., Aoki N., Kuwahara S., Hosojima M., Kaseda R., Goto S., Iida T., De S., Kabasawa H., Kaneko R., et al. Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity. J. Am. Soc. Nephrol. 2017;28:1783–1791. doi: 10.1681/ASN.2016060606. PubMed DOI PMC

Balakumar P., Rohilla A., Thangathirupathi A. Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? Pharmacol. Res. 2010;62:179–186. doi: 10.1016/j.phrs.2010.04.004. PubMed DOI

Xu G., Mo L., Wu C., Shen X., Dong H., Yu L., Pan P., Pan K. The miR-15a-5p-XIST-CUL3 regulatory axis is important for sepsis-induced acute kidney injury. Ren. Fail. 2019;41:955–966. doi: 10.1080/0886022X.2019.1669460. PubMed DOI PMC

Lou Y., Huang Z. microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2. Exp. Ther. Med. 2020;19:3060–3068. doi: 10.3892/etm.2020.8547. PubMed DOI PMC

Wang Z.M., Wan X.H., Sang G.Y., Zhao J.D., Zhu Q.Y., Wang D.M. miR-15a-5p suppresses endometrial cancer cell growth via Wnt/β-catenin signaling pathway by inhibiting WNT3A. Eur. Rev. Med. Pharmacol. Sci. 2017;21:4810–4818. PubMed

Chen D., Wu D., Shao K., Ye B., Huang J., Gao Y. MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia. Am. J. Transl. Res. 2017;9:4308–4316. PubMed PMC

Shang J., He Q., Chen Y., Yu D., Sun L., Cheng G., Liu D., Xiao J., Zhao Z. miR-15a-5p suppresses inflammation and fibrosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA. J. Cell. Physiol. 2019;234:9746–9755. doi: 10.1002/jcp.27660. PubMed DOI

Caserta S., Kern F., Cohen J., Drage S., Newbury S.F., Llewelyn M.J. Circulating Plasma microRNAs can differentiate Human Sepsis and Systemic Inflammatory Response Syndrome (SIRS) Sci. Rep. 2016;6:28006. doi: 10.1038/srep28006. PubMed DOI PMC

Caserta S., Mengozzi M., Kern F., Newbury S.F., Ghezzi P., Llewelyn M.J. Severity of Systemic Inflammatory Response Syndrome Affects the Blood Levels of Circulating Inflammatory-Relevant MicroRNAs. Front. Immunol. 2018;8:1977. doi: 10.3389/fimmu.2017.01977. PubMed DOI PMC

Zou Y.F., Wen D., Zhao Q., Shen P.Y., Shi H., Zhao Q., Chen Y.X., Zhang W. Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury. Exp. Biol. Med. 2017;242:657–667. doi: 10.1177/1535370216685005. PubMed DOI PMC

Cai H., Jiang Z., Yang X., Lin J., Cai Q., Li X. Circular RNA HIPK3 contributes to hyperglycemia and insulin homeostasis by sponging miR-192-5p and upregulating transcription factor forkhead box O1. Endocr. J. 2020;67:397–408. doi: 10.1507/endocrj.EJ19-0271. PubMed DOI

Baker M.A., Wang F., Liu Y., Kriegel A.J., Geurts A.M., Usa K., Xue H., Wang D., Kong Y., Liang M. MiR-192-5p in the Kidney Protects Against the Development of Hypertension. Hypertension. 2019;73:399–406. doi: 10.1161/HYPERTENSIONAHA.118.11875. PubMed DOI PMC

Chen J., Wang J., Li H., Wang S., Xiang X., Zhang D. p53 activates miR-192-5p to mediate vancomycin induced AKI. Sci. Rep. 2016;6:38868. doi: 10.1038/srep38868. PubMed DOI PMC

Elton T.S., Selemon H., Elton S.M., Parinandi N.L. Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 2013;532:1–12. doi: 10.1016/j.gene.2012.12.009. PubMed DOI

Pfeiffer D., Roßmanith E., Lang I., Falkenhagen D. miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model. PLoS ONE. 2017;12:e0179850. doi: 10.1371/journal.pone.0179850. PubMed DOI PMC

Alexander M., Hu R., Runtsch M.C., Kagele D.A., Mosbruger T.L., Tolmachova T., Seabra M.C., Round J.L., Ward D.M., O’Connell R.M. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Commun. 2015;6:7321. doi: 10.1038/ncomms8321. PubMed DOI PMC

Johnson B.J., Le T.T., Dobbin C.A., Banovic T., Howard C.B., Flores F.D.M.L., Vanags D., Naylor D.J., Hill G.R., Suhrbier A. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J. Biol. Chem. 2005;280:4037–4047. doi: 10.1074/jbc.M411569200. PubMed DOI

Saikumar J., Hoffmann D., Kim T.M., Gonzalez V.R., Zhang Q., Goering P.L., Brown R.P., Bijol V., Park P.J., Waikar S.S., et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol. Sci. 2012;129:256–267. doi: 10.1093/toxsci/kfs210. PubMed DOI PMC

Lu C., Chen B., Chen C., Li H., Wang D., Tan Y., Weng H. CircNr1h4 regulates the pathological process of renal injury in salt-sensitive hypertensive mice by targeting miR-155-5p. J. Cell. Mol. Med. 2020;24:1700–1712. doi: 10.1111/jcmm.14863. PubMed DOI PMC

Wang Y., Zheng Z.J., Jia Y.J., Yang Y.L., Xue Y.M. Role of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J. Transl. Med. 2018;16:146. doi: 10.1186/s12967-018-1486-7. PubMed DOI PMC

Viñas J.L., Burger D., Zimpelmann J., Haneef R., Knoll W., Campbell P., Gutsol A., Carter A., Allan D.S., Burns K.D. Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. Kidney Int. 2016;90:1238–1250. doi: 10.1016/j.kint.2016.07.015. PubMed DOI

Xu J., Li R., Workeneh B., Dong Y., Wang X., Hu Z. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012;82:401–411. doi: 10.1038/ki.2012.84. PubMed DOI PMC

Regmi A., Liu G., Zhong X., Hu S., Ma R., Gou L., Zafar M.I., Chen L. Evaluation of Serum microRNAs in Patients with Diabetic Kidney Disease: A Nested Case-Controlled Study and Bioinformatics Analysis. Med. Sci. Monit. 2019;25:1699–1708. doi: 10.12659/MSM.913265. PubMed DOI PMC

Chai X., Si H., Song J., Chong Y., Wang J., Zhao G. miR-486-5p Inhibits Inflammatory Response, Matrix Degradation and Apoptosis of Nucleus Pulposus Cells through Directly Targeting FOXO1 in Intervertebral Disc Degeneration. Cell. Physiol. Biochem. 2019;52:109–118. PubMed

Yuan X.P., Liu L.S., Chen C.B., Zhou J., Zheng Y.T., Wang X.P., Han M., Wang C.X. MicroRNA-423-5p facilitates hypoxia/reoxygenation-induced apoptosis in renal proximal tubular epithelial cells by targeting GSTM1 via endoplasmic reticulum stress. Oncotarget. 2017;8:82064–82077. doi: 10.18632/oncotarget.18289. PubMed DOI PMC

Wang W., Gao J., Wang F. MiR-663a/MiR-423-5p are involved in the pathogenesis of lupus nephritis via modulating the activation of NF-κB by targeting TNIP2. Am. J. Transl. Res. 2017;9:3796–3803. PubMed PMC

Xu Y., Zhang J., Fan L., He X. miR-423-5p suppresses high-glucose-induced podocyte injury by targeting Nox4. Biochem. Biophys. Res. Commun. 2018;505:339–345. doi: 10.1016/j.bbrc.2018.09.067. PubMed DOI

Montomoli J., Donati A., Ince C. Acute Kidney Injury and Fluid Resuscitation in Septic Patients: Are We Protecting the Kidney? Nephron. 2019;143:170–173. doi: 10.1159/000501748. PubMed DOI PMC

O’Connor M.E., Prowle J.R. Fluid Overload. Crit. Care Clin. 2015;31:803–821. doi: 10.1016/j.ccc.2015.06.013. PubMed DOI

Bellomo R., Kellum J.A., Ronco C., Wald R., Martensson J., Maiden M., Bagshaw S.M., Glassford N.J., Lankadeva Y., Vaara S.T., et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43:816–828. doi: 10.1007/s00134-017-4755-7. PubMed DOI

Gaudry S., Hajage D., Benichou N., Chaïbi K., Barbar S., Zarbock A., Lumlertgul N., Wald R., Bagshaw S.M., Srisawat N., et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: A systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2020;395:1506–1515. doi: 10.1016/S0140-6736(20)30531-6. PubMed DOI

Gaudry S., Hajage D., Schortgen F., Martin-Lefevre L., Pons B., Boulet E., Boyer A., Chevrel G., Lerolle N., Carpentier D., et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N. Engl. J. Med. 2016;375:122–133. doi: 10.1056/NEJMoa1603017. PubMed DOI

Karkar A., Ronco C. Prescription of CRRT: A pathway to optimize therapy. Ann. Intensive Care. 2020;10:32. doi: 10.1186/s13613-020-0648-y. PubMed DOI PMC

Romagnoli S., Ricci Z., Ronco C. CRRT for sepsis-induced acute kidney injury. Curr. Opin. Crit. Care. 2018;24:483–492. doi: 10.1097/MCC.0000000000000544. PubMed DOI

Petejova N., Martinek A., Zahalkova J., Duricova J., Brozmannova H., Urbanek K., Grundmann M., Plasek J., Kacirova I. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed. Pap. Med. Faculty Univ. Palacky Olomouc Czech Repub. 2014;158:65–72. doi: 10.5507/bp.2012.092. PubMed DOI

Petejova N., Zahalkova J., Duricova J., Kacirova I., Brozmanova H., Urbanek K., Grundmann M., Martinek A. Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J. Chemother. 2012;24:107–112. doi: 10.1179/1120009X12Z.0000000006. PubMed DOI